Crossmark

Evaluating the Impact and Benefits of Fluticasone Furoate/Vilanterol in Individuals with Asthma or COPD: A Mixed-Methods Analysis of Patient Experiences

Crossref DOI link: https://doi.org/10.1007/s12325-018-0760-7

Published Online: 2018-08-13

Published Print: 2018-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Svedsater, Henrik

Doll, Helen A.

Macey, Jake

Miles, Gail

Bradshaw, Lisa

Vanya, Magdalena
Funding

Funding for this research was provided by:

GlaxoSmithKline foundation (HO-15-15503/204888)
More Information

Article History

Received: 18 May 2018

First Online: 13 August 2018

Change Date: 3 September 2021

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s12325-021-01901-9

Updates are available Correction dated 2021-09-03

Click to view Correction: https://doi.org/10.1007/s12325-021-01901-9